Wednesday, October 7, 2026
ExploreSearch
Via News

Trading Platforms

2 articles

MEXC's Push Into Traditional Assets Raises Licensing Red Flags, Risk Analysis Finds

MEXC's Push Into Traditional Assets Raises Licensing Red Flags, Risk Analysis Finds

MEXC's expansion from crypto trading into tokenized and traditional financial assets could trigger securities licensing requirements the exchange does not currently hold, according to a regulatory risk assessment. The shift exposes CEO Vugar and the exchange to scrutiny from financial regulators who treat TradFi offerings differently than pure crypto products.

LM Salvado•
Digital Asset Mortgages Launch as Traditional Finance Integrates Crypto Collateral

Digital Asset Mortgages Launch as Traditional Finance Integrates Crypto Collateral

Better Home & Finance introduced token-backed mortgages that let Americans use crypto holdings as collateral, marking the first AI-native lender to bridge digital wealth with homeownership. The product enables borrowers lacking downpayment funds to pledge tokenized assets rather than liquidating positions. The launch signals traditional finance infrastructure systematically integrating blockchain-based collateral across lending, trading, and payment systems.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com